All In Biotech

Drug Trial Radar · NCT06452498

Preeclampsia Intervention Netherlands

Metformin for the Prolongation of Pregnancy in Preterm Preeclampsia

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Sep 19, 2025

Primary completion

Mar 19, 2029

Study completion Jun 19, 2029

Sponsor

Lead sponsor
Amsterdam UMCAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
ZonMw: The Netherlands Organisation for Health Research and Development
First posted
Jun 11, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this study is to find out if pregnant individuals with preterm preeclampsia (PE) who are treated with metformin can stay pregnant for longer, and if this is safe(r) for the mother and child. Preterm PE affects about 1 in 100 pregnant individuals in the Netherlands. Signs of preterm PE can be high blood pressure and protein in the urine in the second half of pregnancy (but before 32-34 weeks of pregnancy). Other symptoms can develop, such as problems with blood clotting and how well the blood cells, liver, lungs, and brain work. The disease can lead to serious complications for both the mother and child. The only way to cure preterm PE is to make sure the child is born, and many times, children have to be delivered (very) early (before 37 weeks). Children born (very) early can suffer from infections, breathing difficulties, and problems in their development. Metformin is a medicine used to treat high blood sugar during and outside of pregnancy. In a previous study in South Africa, women with preterm PE that used metformin were able to safely remain pregnant for an extra week. Similarly, the main goal of the Preeclampsia Intervention NetherLands (PI-NL) study is to see if patients with preterm PE in the Netherlands that use metformin can remain pregnant for a longer time than patients taking a placebo. A placebo is a look-a-like capsule that contains no active ingredients. Researchers, the treating medical team, and participants will not know which participant gets which treatment. In addition, all participants will receive the standard care that all preterm PE patients get.

Conditions

  • Pre-Eclampsia Onset Less Than 37 Weeks
  • Pre-Eclampsia
  • Pre-Eclampsia; Complicating Pregnancy
  • Pre-Eclampsia as Antepartum Condition
  • Pre-eclampsia or Eclampsia With Pre-existing Hypertension
  • Pre-Eclampsia; Affecting Fetus
  • HELLP Syndrome Complicating Pregnancy
  • HELLP Syndrome
  • HELLP

Interventions

  • Metformin HydrochlorideDrug

    Metformin Hydrochloride encapsulated immediate-release tablet of 500 mg, backfilled with cellulose.

  • PlaceboDrug

    Capsule filled with cellulose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of days between randomization and deliveryTime frame: Time between randomization and delivery (up to 37 weeks of gestation)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Amsterdam UMC

    Amsterdam, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.